These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 1856140)

  • 21. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer.
    Pession A; Prete A; Paolucci G
    Chemotherapy; 1997; 43(5):358-66. PubMed ID: 9309370
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies for cost-containment: once-daily ceftriaxone plus amikacin as empiric therapy for febrile granulocytopenic children with cancer.
    Castagnola E; Lanino E; Giacchino R; Viscoli C; Dini G
    J Chemother; 1999 Feb; 11(1):54-60. PubMed ID: 10078782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamics of ceftazidime administered as continuous infusion or intermittent bolus alone and in combination with single daily-dose amikacin against Pseudomonas aeruginosa in an in vitro infection model.
    Cappelletty DM; Kang SL; Palmer SM; Rybak MJ
    Antimicrob Agents Chemother; 1995 Aug; 39(8):1797-801. PubMed ID: 7486921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis.
    Abdel-Hady E; El Hamamsy M; Hedaya M; Awad H
    J Clin Pharm Ther; 2011 Feb; 36(1):45-52. PubMed ID: 21198719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind study of the efficacy and safety of multiple daily doses of amikacin versus one daily dose for children with perforated appendicitis in Costa Rica.
    Pérez V; Saénz D; Madriz J; Harhay M; Feoli J; Castro M; Odio C
    Int J Infect Dis; 2011 Aug; 15(8):e569-75. PubMed ID: 21733727
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic dosing of aminoglycosides: a controlled trial.
    Bartal C; Danon A; Schlaeffer F; Reisenberg K; Alkan M; Smoliakov R; Sidi A; Almog Y
    Am J Med; 2003 Feb; 114(3):194-8. PubMed ID: 12637133
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum pharmacokinetics and sputum penetration of amikacin 30 mg/kg once daily and of ceftazidime 200 mg/kg/day as a continuous infusion in cystic fibrosis patients.
    Byl B; Baran D; Jacobs F; Herschuelz A; Thys JP
    J Antimicrob Chemother; 2001 Aug; 48(2):325-7. PubMed ID: 11481316
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized clinical trial comparing ceftriaxone/amikacin versus ceftazidime/amikacin as initial therapy of febrile episodes in neutropenic patients.
    Yataganas X; Rombos Y; Vayopoulos G; Meletis J; Avlami A
    Chemotherapy; 1991; 37(5):376-81. PubMed ID: 1804599
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ceftriaxone plus conventional or single-daily dose amikacin versus ceftazidime/amikacin as empiric therapy in febrile neutropenic patients.
    Leoni F; Ciolli S; Pascarella A; Fanci R; Caporale R; Rossi Ferrini P
    Chemotherapy; 1993; 39(2):147-52. PubMed ID: 8458248
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Meropenem monotherapy versus combination therapy with ceftazidime and amikacin for empirical treatment of febrile neutropenic patients.
    Behre G; Link H; Maschmeyer G; Meyer P; Paaz U; Wilhelm M; Hiddemann W
    Ann Hematol; 1998 Feb; 76(2):73-80. PubMed ID: 9540761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto Infection Program.
    Cometta A; Calandra T; Gaya H; Zinner SH; de Bock R; Del Favero A; Bucaneve G; Crokaert F; Kern WV; Klastersky J; Langenaeken I; Micozzi A; Padmos A; Paesmans M; Viscoli C; Glauser MP
    Antimicrob Agents Chemother; 1996 May; 40(5):1108-15. PubMed ID: 8723449
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
    Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
    J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An open evaluation of triple antibiotic therapy including vancomycin for febrile bone marrow transplant recipients with severe neutropenia.
    Bosi A; Laszlo D; Bacci S; Fanci R; Guidi S; Saccardi R; Vannucchi AM; Rossi-Ferrini P
    J Chemother; 1999 Aug; 11(4):287-92. PubMed ID: 10465131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A randomised trial of empirical antibiotic therapy in febrile neutropenic patients with hematological disorders: ceftazidime versus azlocillin plus amikacin.
    Gibson J; Date L; Joshua DE; Young GA; Wilson A; Benn R; Benson W; Iland H; Vincent PC; Kronenberg H
    Aust N Z J Med; 1989 Oct; 19(5):417-25. PubMed ID: 2686610
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double beta-lactam combination versus an aminoglycoside-containing regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.
    De Jongh CA; Joshi JH; Thompson BW; Newman KA; Finley RS; Moody MR; Salvatore PC; Tenney JH; Drusano GL; Schimpff SC
    Am J Med; 1986 May; 80(5C):101-11. PubMed ID: 3521269
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cefotaxime plus amikacin as empiric therapy in the treatment of febrile episodes in neutropenic patients with hematologic malignancies.
    Martino P; Venditti M; Petti MC; Mandelli F; Serra P
    Infection; 1985; 13(3):125-9. PubMed ID: 3928495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients.
    Krivoy N; Postovsky S; Elhasid R; Ben Arush MW
    Infection; 1998; 26(6):396-8. PubMed ID: 9861567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cefepime/amikacin versus ceftazidime/amikacin as empirical therapy for febrile episodes in neutropenic patients: a comparative study. The French Cefepime Study Group.
    Cordonnier C; Herbrecht R; Pico JL; Gardembas M; Delmer A; Delain M; Moreau P; Ladeb S; Nalet V; Rollin C; Gres JJ
    Clin Infect Dis; 1997 Jan; 24(1):41-51. PubMed ID: 8994754
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ceftriaxone versus ceftazidime plus aminoglycoside therapy for infections in patients with neutropenia after cytotoxic chemotherapy. Short communication.
    Krcméry V; Danisovicová A; Drgona L; Spánik S; Fuchsberger P; Korec S; Svec J
    Neoplasma; 1993; 40(2):103-5. PubMed ID: 8350953
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.